Pharma: Important study success for cancer vaccine: Moderna stock rises by 90 percent
For the first time, a personalized cancer vaccine has shown positive results in a crucial study. Analysts are talking about a scientific breakthrough.
Moderna's stock surged over 90 percent to nearly $120 on Wednesday at the Wall Street, its highest level since July 2024, after positive results from a major study on a skin cancer vaccine developed with Merck. The vaccine could hit the market as early as 2027. Merck's stock rose around 8 percent to $146. The two companies have been working on the skin cancer vaccine for a decade. The study's success is a significant win for Moderna in the competition for mRNA-based therapies.
Written by urgent.news from Handelsblatt's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.
